BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wong G, Qiu X, Olinger GG, Kobinger GP. Post-exposure therapy of filovirus infections. Trends Microbiol 2014;22:456-63. [PMID: 24794572 DOI: 10.1016/j.tim.2014.04.002] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Moekotte AL, Huson MA, van der Ende AJ, Agnandji ST, Huizenga E, Goorhuis A, Grobusch MP. Monoclonal antibodies for the treatment of Ebola virus disease. Expert Opin Investig Drugs 2016;25:1325-35. [PMID: 27676206 DOI: 10.1080/13543784.2016.1240785] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
2 Chippaux JP, Boyer LV, Alagón A. Post-exposure treatment of Ebola virus using passive immunotherapy: proposal for a new strategy. J Venom Anim Toxins Incl Trop Dis 2015;21:3. [PMID: 25705218 DOI: 10.1186/s40409-015-0003-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
3 Jamieson DJ, Uyeki TM, Callaghan WM, Meaney-Delman D, Rasmussen SA. What obstetrician-gynecologists should know about Ebola: a perspective from the Centers for Disease Control and Prevention. Obstet Gynecol 2014;124:1005-10. [PMID: 25203368 DOI: 10.1097/AOG.0000000000000533] [Cited by in Crossref: 67] [Cited by in F6Publishing: 30] [Article Influence: 9.6] [Reference Citation Analysis]
4 Fedson DS. A practical treatment for patients with Ebola virus disease. J Infect Dis 2015;211:661-2. [PMID: 25160984 DOI: 10.1093/infdis/jiu474] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
5 Saphire EO, Aman MJ. Feverish Quest for Ebola Immunotherapy: Straight or Cocktail? Trends Microbiol 2016;24:684-6. [PMID: 27338027 DOI: 10.1016/j.tim.2016.05.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
6 Chippaux JP. Outbreaks of Ebola virus disease in Africa: the beginnings of a tragic saga. J Venom Anim Toxins Incl Trop Dis 2014;20:44. [PMID: 25320574 DOI: 10.1186/1678-9199-20-44] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
7 Bazhan SI, Antonets DV, Karpenko LI, Oreshkova SF, Kaplina ON, Starostina EV, Dudko SG, Fedotova SA, Ilyichev AA. In silico Designed Ebola Virus T-Cell Multi-Epitope DNA Vaccine Constructions Are Immunogenic in Mice. Vaccines (Basel) 2019;7:E34. [PMID: 30934980 DOI: 10.3390/vaccines7020034] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
8 Kroeker A, Griffin BD, Qiu X, Kobinger G. Assessing Antiviral Countermeasures Using Mouse Models of Ebolavirus Infection. Methods Mol Biol 2017;1628:273-82. [PMID: 28573628 DOI: 10.1007/978-1-4939-7116-9_22] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Jerebtsova M, Nekhai S. Therapeutics for postexposure treatment of Ebola virus infection. Future Virol 2015;10:221-32. [PMID: 26213559 DOI: 10.2217/fvl.14.109] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
10 Wong G, Kobinger GP. Backs against the wall: novel and existing strategies used during the 2014-2015 Ebola virus outbreak. Clin Microbiol Rev 2015;28:593-601. [PMID: 25972518 DOI: 10.1128/CMR.00014-15] [Cited by in Crossref: 37] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
11 Marzi A, Hanley PW, Haddock E, Martellaro C, Kobinger G, Feldmann H. Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona. J Infect Dis 2016;214:S360-6. [PMID: 27496978 DOI: 10.1093/infdis/jiw218] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 6.7] [Reference Citation Analysis]
12 Kilgore PE, Grabenstein JD, Salim AM, Rybak M. Treatment of Ebola Virus Disease. Pharmacotherapy 2015;35:43-53. [DOI: 10.1002/phar.1545] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 5.9] [Reference Citation Analysis]
13 Luthra P, Aguirre S, Yen BC, Pietzsch CA, Sanchez-Aparicio MT, Tigabu B, Morlock LK, García-Sastre A, Leung DW, Williams NS, Fernandez-Sesma A, Bukreyev A, Basler CF. Topoisomerase II Inhibitors Induce DNA Damage-Dependent Interferon Responses Circumventing Ebola Virus Immune Evasion. mBio 2017;8:e00368-17. [PMID: 28377530 DOI: 10.1128/mBio.00368-17] [Cited by in Crossref: 40] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
14 Jahrling PB, Hensley LE, Barrett K, Lane HC, Davey RT. State-of-the-Art Workshops on Medical Countermeasures Potentially Available for Human Use Following Accidental Exposures to Ebola Virus. J Infect Dis 2015;212 Suppl 2:S84-90. [PMID: 25957962 DOI: 10.1093/infdis/jiv115] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
15 McElroy AK, Spiropoulou CF. Biomarkers for understanding Ebola virus disease. Biomark Med 2014;8:1053-6. [PMID: 25402574 DOI: 10.2217/bmm.14.75] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
16 Johansen LM, DeWald LE, Shoemaker CJ, Hoffstrom BG, Lear-Rooney CM, Stossel A, Nelson E, Delos SE, Simmons JA, Grenier JM, Pierce LT, Pajouhesh H, Lehár J, Hensley LE, Glass PJ, White JM, Olinger GG. A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity. Sci Transl Med 2015;7:290ra89. [PMID: 26041706 DOI: 10.1126/scitranslmed.aaa5597] [Cited by in Crossref: 170] [Cited by in F6Publishing: 147] [Article Influence: 28.3] [Reference Citation Analysis]
17 Dowall SD, Bosworth A, Rayner E, Taylor I, Landon J, Cameron I, Coxon R, Al Abdulla I, Graham VA, Hall G, Kobinger G, Hewson R, Carroll MW. Post-exposure treatment of Ebola virus disease in guinea pigs using EBOTAb, an ovine antibody-based therapeutic. Sci Rep 2016;6:30497. [PMID: 27465308 DOI: 10.1038/srep30497] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
18 Ilinykh PA, Huang K, Santos RI, Gilchuk P, Gunn BM, Karim MM, Liang J, Fouch ME, Davidson E, Parekh DV, Kimble JB, Pietzsch CA, Meyer M, Kuzmina NA, Zeitlin L, Saphire EO, Alter G, Crowe JE Jr, Bukreyev A. Non-neutralizing Antibodies from a Marburg Infection Survivor Mediate Protection by Fc-Effector Functions and by Enhancing Efficacy of Other Antibodies. Cell Host Microbe 2020;27:976-991.e11. [PMID: 32320678 DOI: 10.1016/j.chom.2020.03.025] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
19 Mwangi W, de Figueiredo P, Criscitiello MF. One Health: Addressing Global Challenges at the Nexus of Human, Animal, and Environmental Health. PLoS Pathog 2016;12:e1005731. [PMID: 27631500 DOI: 10.1371/journal.ppat.1005731] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
20 Shurtleff AC, Bavari S. Animal models for ebolavirus countermeasures discovery: what defines a useful model? Expert Opin Drug Discov 2015;10:685-702. [PMID: 26004783 DOI: 10.1517/17460441.2015.1035252] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
21 Elshabrawy HA, Erickson TB, Prabhakar BS. Ebola virus outbreak, updates on current therapeutic strategies. Rev Med Virol 2015;25:241-53. [PMID: 25962887 DOI: 10.1002/rmv.1841] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
22 Chen G, Sidhu SS, Nilvebrant J. Synthetic Antibodies in Infectious Disease. Adv Exp Med Biol 2017;1053:79-98. [PMID: 29549636 DOI: 10.1007/978-3-319-72077-7_5] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Jain S, Khaiboullina SF, Baranwal M. Immunological Perspective for Ebola Virus Infection and Various Treatment Measures Taken to Fight the Disease. Pathogens 2020;9:E850. [PMID: 33080902 DOI: 10.3390/pathogens9100850] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
24 Garrison AR, Giomarelli BG, Lear-Rooney CM, Saucedo CJ, Yellayi S, Krumpe LR, Rose M, Paragas J, Bray M, Olinger GG Jr, McMahon JB, Huggins J, O'Keefe BR. The cyanobacterial lectin scytovirin displays potent in vitro and in vivo activity against Zaire Ebola virus. Antiviral Res 2014;112:1-7. [PMID: 25265598 DOI: 10.1016/j.antiviral.2014.09.012] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 4.9] [Reference Citation Analysis]
25 De Clercq E. Ebola virus (EBOV) infection: Therapeutic strategies. Biochem Pharmacol 2015;93:1-10. [PMID: 25481298 DOI: 10.1016/j.bcp.2014.11.008] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 6.3] [Reference Citation Analysis]
26 Choi JH, Jonsson-Schmunk K, Qiu X, Shedlock DJ, Strong J, Xu JX, Michie KL, Audet J, Fernando L, Myers MJ, Weiner D, Bajrovic I, Tran LQ, Wong G, Bello A, Kobinger GP, Schafer SC, Croyle MA. A Single Dose Respiratory Recombinant Adenovirus-Based Vaccine Provides Long-Term Protection for Non-Human Primates from Lethal Ebola Infection. Mol Pharm 2015;12:2712-31. [PMID: 25363619 DOI: 10.1021/mp500646d] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
27 Liu Y, Xiao J, Zhang B, Shelite TR, Su Z, Chang Q, Judy B, Li X, Drelich A, Bei J, Zhou Y, Zheng J, Jin Y, Rossi SL, Tang SJ, Wakamiya M, Saito T, Ksiazek T, Kaphalia B, Gong B. Increased talin-vinculin spatial proximities in livers in response to spotted fever group rickettsial and Ebola virus infections. Lab Invest 2020;100:1030-41. [PMID: 32238906 DOI: 10.1038/s41374-020-0420-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
28 Fedson DS, Rordam OM. Treating Ebola patients: a 'bottom up' approach using generic statins and angiotensin receptor blockers. Int J Infect Dis 2015;36:80-4. [PMID: 26143190 DOI: 10.1016/j.ijid.2015.04.019] [Cited by in Crossref: 35] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
29 Murin CD, Fusco ML, Bornholdt ZA, Qiu X, Olinger GG, Zeitlin L, Kobinger GP, Ward AB, Saphire EO. Structures of protective antibodies reveal sites of vulnerability on Ebola virus. Proc Natl Acad Sci U S A 2014;111:17182-7. [PMID: 25404321 DOI: 10.1073/pnas.1414164111] [Cited by in Crossref: 147] [Cited by in F6Publishing: 131] [Article Influence: 18.4] [Reference Citation Analysis]
30 MenkinSmith L, Lehman-Huskamp K, Schaefer J, Alfred M, Catchpole K, Pockrus B, Wilson DA, Reves JG. A Pilot Trial of Online Simulation Training for Ebola Response Education. Health Secur 2018;16:391-401. [PMID: 30489171 DOI: 10.1089/hs.2018.0055] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
31 Wong G, Richardson JS, Pillet S, Racine T, Patel A, Soule G, Ennis J, Turner J, Qiu X, Kobinger GP. Adenovirus-Vectored Vaccine Provides Postexposure Protection to Ebola Virus-Infected Nonhuman Primates. J Infect Dis 2015;212 Suppl 2:S379-83. [PMID: 25957963 DOI: 10.1093/infdis/jiv102] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
32 Fedson DS, Jacobson JR, Rordam OM, Opal SM. Treating the Host Response to Ebola Virus Disease with Generic Statins and Angiotensin Receptor Blockers. mBio 2015;6:e00716. [PMID: 26106080 DOI: 10.1128/mBio.00716-15] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.9] [Reference Citation Analysis]
33 Tambunan USF, Alkaff AH, Nasution MAF, Parikesit AA, Kerami D. Screening of commercial cyclic peptide conjugated to HIV-1 Tat peptide as inhibitor of N-terminal heptad repeat glycoprotein-2 ectodomain Ebola virus through in silico analysis. J Mol Graph Model 2017;74:366-78. [PMID: 28482272 DOI: 10.1016/j.jmgm.2017.04.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 2.6] [Reference Citation Analysis]
34 Wang H, Wong G, Zhu W, He S, Zhao Y, Yan F, Rahim MN, Bi Y, Zhang Z, Cheng K, Jin H, Cao Z, Zheng X, Gai W, Bai J, Chen W, Zou Y, Gao Y, Gao GF, Yang S, Xia X, Qiu X. Equine-Origin Immunoglobulin Fragments Protect Nonhuman Primates from Ebola Virus Disease. J Virol 2019;93:e01548-18. [PMID: 30541860 DOI: 10.1128/JVI.01548-18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
35 Hamid KM, Yusuf I, Onoja BA, Koki AY. Knowledge, attitude and practice of medical laboratory practitioners in the fight against Ebola virus disease. Journal of Virus Eradication 2018;4:1-5. [DOI: 10.1016/s2055-6640(20)30233-8] [Cited by in Crossref: 4] [Article Influence: 1.0] [Reference Citation Analysis]
36 Janeba Z. Development of Small-Molecule Antivirals for Ebola. Med Res Rev 2015;35:1175-94. [PMID: 26172225 DOI: 10.1002/med.21355] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
37 Su Z, Chang Q, Drelich A, Shelite T, Judy B, Liu Y, Xiao J, Zhou C, He X, Jin Y, Saito T, Tang S, Soong L, Wakamiya M, Fang X, Bukreyev A, Ksiazek T, Russell WK, Gong B. Annexin A2 depletion exacerbates the intracerebral microhemorrhage induced by acute rickettsia and Ebola virus infections. PLoS Negl Trop Dis 2020;14:e0007960. [PMID: 32687500 DOI: 10.1371/journal.pntd.0007960] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
38 Singh RK, Dhama K, Malik YS, Ramakrishnan MA, Karthik K, Khandia R, Tiwari R, Munjal A, Saminathan M, Sachan S, Desingu PA, Kattoor JJ, Iqbal HM, Joshi SK. Ebola virus - epidemiology, diagnosis, and control: threat to humans, lessons learnt, and preparedness plans - an update on its 40 year's journey. Vet Q 2017;37:98-135. [PMID: 28317453 DOI: 10.1080/01652176.2017.1309474] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
39 Dhanda SK, Chaudhary K, Gupta S, Brahmachari SK, Raghava GP. A web-based resource for designing therapeutics against Ebola Virus. Sci Rep 2016;6:24782. [PMID: 27113850 DOI: 10.1038/srep24782] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
40 Martyushev A, Nakaoka S, Sato K, Noda T, Iwami S. Modelling Ebola virus dynamics: Implications for therapy. Antiviral Res 2016;135:62-73. [PMID: 27743917 DOI: 10.1016/j.antiviral.2016.10.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
41 Hoenen T, Feldmann H. Ebolavirus in West Africa, and the use of experimental therapies or vaccines. BMC Biol 2014;12:80. [PMID: 25286348 DOI: 10.1186/s12915-014-0080-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
42 Smither SJ, Nelson M, Eastaugh L, Nunez A, Salguero FJ, Lever MS. Experimental Respiratory Infection of Marmosets (Callithrix jacchus) With Ebola Virus Kikwit. J Infect Dis 2015;212 Suppl 2:S336-45. [PMID: 26209682 DOI: 10.1093/infdis/jiv371] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
43 Hacke M, Björkholm P, Hellwig A, Himmels P, Ruiz de Almodóvar C, Brügger B, Wieland F, Ernst AM. Inhibition of Ebola virus glycoprotein-mediated cytotoxicity by targeting its transmembrane domain and cholesterol. Nat Commun 2015;6:7688. [PMID: 26158910 DOI: 10.1038/ncomms8688] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
44 Drelich A, Judy B, He X, Chang Q, Yu S, Li X, Lu F, Wakamiya M, Popov V, Zhou J, Ksiazek T, Gong B. Exchange Protein Directly Activated by cAMP Modulates Ebola Virus Uptake into Vascular Endothelial Cells. Viruses 2018;10:E563. [PMID: 30332733 DOI: 10.3390/v10100563] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]